Net revenues for the second quarter of fiscal 2021 decreased compared to the same period in the prior year primarily due to lower equipment sales to HDD manufacturers, lower Photonics product sales and lower Photonics contract R&D. TFE did not recognize revenue on any systems in the second quarter of fiscal 2021. TFE recognized revenue on two 200 Lean
®
HDD systems in the second quarter of fiscal 2020. During the second quarter of fiscal 2021, Photonics delivered the first prototype units for our U.S. Army Integrated Visual Augmentation System (“IVAS”) product. During the second quarter of fiscal 2021, the Company did not receive any government assistance related to
COVID-19
from the government of Singapore. During the second quarter of fiscal 2020, the Company received $310,000 in government assistance related to
COVID-19
from the government of Singapore of which $180,000 was reported as a reduction of cost of net revenues, $49,000 was reported as a reduction of R&D expenses and $81,000 was reported as a reduction of selling, general and administrative expenses. The Company reported a net loss for the second quarter of fiscal 2021 compared to net income for the second quarter of 2020 due to lower revenues, lower gross profit and higher R&D expenses, offset in part by lower selling, general and administrative expenses.
Net revenues for the first six months of fiscal 2021 decreased compared to the same period in the prior year primarily due to lower equipment sales to HDD manufacturers, lower Photonics product sales and lower Photonics contract R&D revenue, offset in part by higher equipment sales for advanced semiconductor packaging. TFE recognized revenue on one MATRIX PVD system for advanced semiconductor packaging in the first half of fiscal 2021 compared to two 200 Lean
HDD systems in the first half of fiscal 2020. During the first half of fiscal 2021, the Company received $66,000 in government assistance related to
COVID-19
from the government of Singapore of which $39,000 was reported as a reduction of cost of net revenues, $10,000 was reported as a reduction of R&D expenses and $17,000 was reported as a reduction of selling, general and administrative expenses. During the first half of fiscal 2020, the Company received $310,000 in government assistance related to
COVID-19
from the government of Singapore of which $180,000 was reported as a reduction of cost of net revenues, $49,000 was reported as a reduction of R&D expenses and $81,000 was reported as a reduction of selling, general and administrative expenses. The Company reported a net loss for the first half of fiscal 2021 compared to net income for the first half of 2020 due to lower revenues, lower gross profit and higher spending on R&D, offset in part by lower selling, general and administrative expenses.
We believe fiscal 2021 will be a challenging year and we do not expect to be profitable in fiscal 2021. We expect that 2021 HDD equipment sales will be lower than 2020 levels. In 2021, we expect to obtain production orders for our VERTEX systems. In 2021, we expect product revenue in Photonics to decline slightly as shipments for the Apache camera under the current contract with the U.S. government concluded in the third quarter of 2020. In 2021, we will continue to deliver product shipments of the night-vision camera modules for the F35 Joint Strike Fighter program and our LIVAR cameras for advanced precision targeting systems. In 2021, we expect decreased contract R&D revenue as development work on the multi-year IVAS contract award for the development and production of digital night-vision cameras to support the U.S. Army’s IVAS program completed in early 2021. In 2021, we delivered the first prototype units for our IVAS product. We do not expect to receive any additional government assistance related to
COVID-19
from the government of Singapore in the remainder of fiscal 2021.
Updates to the
COVID-19
response included in our Annual Report on
10-K
for the fiscal year ended January 2, 2021
The impact of
COVID-19,
including changes in consumer behavior, pandemic fears, and market downturns, as well as restrictions on business and individual activities, has created significant volatility in the global economy and led to reduced economic activity. Although
COVID-19
vaccines are now broadly distributed and administered, there remains significant uncertainty concerning the magnitude of the impact and the duration of the
COVID-19
pandemic. If new strains of
COVID-19
develop, the continued impacts to our business could be material to our fiscal 2021 results. Our customers may delay or cancel orders due to reduced demand, supply chain disruptions, and/or travel restrictions and border closures. We have experienced pandemic-related delays in our TFE evaluation and development work. In response
to COVID-19,
we implemented initiatives to safeguard our employees, including work-from-home protocols. In June 2021 we began reopening our offices on a regional basis in accordance with local authority guidelines while ensuring that our return to work is thoughtful, prudent, and handled with a safety-first approach. All employees in the United States who could work from home did so through the middle of June 2021 when we fully reopened our offices as restrictions were lifted by the applicable authorities. All employees in Singapore that can do so continue to work remotely and will do so until restrictions are lifted by the applicable authorities in Singapore. Our employees’ health and safety is our top priority, and we will continue to monitor local restrictions across the world, the administration of vaccines, and the number of new cases.
In Singapore, Intevac receives government assistance under the Job Support Scheme (“JSS”). The purpose of the JSS is to provide wage support to employers to help them retain their local employees. Under the JSS, Intevac received $66,000 in JSS grants in the first half of fiscal 2021. During the quarter ended June 27, 2020, the Company received $310,000 in JSS grants. Intevac does not expect to receive any additional government assistance related to
COVID-19
from the government of Singapore in the remainder of fiscal 2021.